Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q86VD7

UPID:
S2542_HUMAN

ALTERNATIVE NAMES:
Solute carrier family 25 member 42

ALTERNATIVE UPACC:
Q86VD7; D2T2J5; O14553; O43378

BACKGROUND:
Mitochondrial coenzyme A transporter SLC25A42, also known as Solute carrier family 25 member 42, is essential for mitochondrial function and energy production. It mediates the transport of coenzyme A, a critical cofactor in metabolic processes, ensuring efficient energy flow within cells. The protein's role in coenzyme A transport underscores its significance in cellular metabolism and mitochondrial health.

THERAPEUTIC SIGNIFICANCE:
The involvement of SLC25A42 in a rare autosomal recessive disorder with symptoms ranging from lactic acidosis to severe neurological regression points to its critical role in human health. The disease's link to SLC25A42 mutations provides a unique opportunity for drug discovery, focusing on modulating this protein's function. Targeting SLC25A42 could lead to innovative treatments for patients suffering from related metabolic and neurologic disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.